Oren Ilan 4

What Happened
Oren Ilan, a director of Roivant Sciences (ROIV), received an award of 1,164 common shares under the company's Non-Employee Director Compensation Plan on January 20, 2026 (reported as an acquisition at $0.00). To satisfy tax withholding obligations on the vesting/settlement, 124 shares were net-settled/disposed at $22.98 per share, reported as $2,850. The award was fully vested as of the grant date.

Key Details

• Transaction dates: January 20, 2026; Form 4 filed January 22, 2026 (within the standard 2-business-day reporting window).
• Award: 1,164 shares granted at $0.00 (code A).
• Tax withholding/net settlement: 124 shares surrendered at $22.98 each (code F), proceeds reported $2,850.
• Shares owned after transaction: not stated in the provided summary.
• Footnotes: F1 — award fully vested on grant date. F2 — 124-share disposition reflects issuer’s net settlement to satisfy tax withholding.

Context
This is a routine equity compensation vesting and net-settlement for taxes, not an open-market buy or sell reflecting a trading decision. Net-settlements to cover taxes (code F) are common and generally indicate standard administrative withholding rather than a deliberate sale for investment purposes.